Aerpio Pharmaceuticals Inc. [NASDAQ: ARPO] gained 2.33% or 0.03 points to close at $1.32 with a heavy trading volume of 3431143 shares. The company report on August 4, 2020 that Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19.
Aerpio Pharmaceuticals, Inc. (“Aerpio”) (Nasdaq: ARPO) and The U.S. Government operating through the Medical Technology Enterprise Consortium (MTEC) announced today that an agreement has been reached to evaluate razuprotafib in a new randomized, investigational trial for the prevention and treatment of Acute Respiratory Distress Syndrome (ARDS) in adult patients with moderate to severe COVID-19 as part of MTEC-20-09-COVID-19 Treatment Military Infectious Disease Research Program (MIDRP) “Development of Treatments for COVID-19.” MTEC will provide up to $5.1 million in funding toward the clinical trial. Aerpio will support the trial with “in kind” spending in the amount of $2.8 million. MTEC is a 501(c)3 non-profit organization constructed by the U.S. Army Medical Research and Development Command (USAMRDC). The Medical Technology Enterprise Consortium (MTEC) was established as an enterprise partnership including industry and academia to facilitate research and development activities. Protecting U.S. forces from COVID-19 is a key priority for the U.S. military. The partnership between Aerpio and MTEC will provide resources to support a second COVID-19 Phase 2 clinical trial with razuprotafib, a drug candidate being investigated for its potential to prevent and treat the severe respiratory distress observed in COVID-19 patients.
Aerpio Pharmaceuticals is developing a potent and selective small molecule inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP), razuprotafib (AKB-9778), that restores Tie2 pathway activation in endothelial cells to stabilize blood vessels during vascular injury and inflammation. Emerging data indicate that SARS-Cov2, the virus that causes COVID-19, may attack vascular endothelium and destabilize blood vessels in multiple organs including the lung, kidneys and heart leading to substantial morbidity and mortality. Based on these findings, Aerpio and a distinguished team of clinical investigators have developed a plan to investigate the therapeutic potential of subcutaneous razuprotafib for the prevention and treatment of ARDS in patients with moderate to severe COVID-19. .
It opened the trading session at $1.29, the shares rose to $1.321 and dropped to $1.26, the range by which the price of stock traded the whole day. The daily chart for ARPO points out that the company has recorded 90.23% gains over the past six months. However, it is still -214.29% lower than its most recent low trading price.
If we look at the average trading volume of 2.41M shares, ARPO reached to a volume of 3431143 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Aerpio Pharmaceuticals Inc. [ARPO]:
Needham have made an estimate for Aerpio Pharmaceuticals Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on July 23, 2018.
The Average True Range (ATR) for Aerpio Pharmaceuticals Inc. is set at 0.11 The Price to Book ratio for the last quarter was 1.63, with the Price to Cash per share for the same quarter was set at 0.83.
Trading performance analysis for ARPO stock
Aerpio Pharmaceuticals Inc. [ARPO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.49. With this latest performance, ARPO shares gained by 3.13% in over the last four-week period, additionally plugging by 90.23% over the last 6 months – not to mention a rise of 78.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ARPO stock in for the last two-week period is set at 50.34, with the RSI for the last a single of trading hit 47.69, and the three-weeks RSI is set at 53.68 for Aerpio Pharmaceuticals Inc. [ARPO]. The present Moving Average for the last 50 days of trading for this stock 1.2559, while it was recorded at 1.2920 for the last single week of trading, and 0.7658 for the last 200 days.
Aerpio Pharmaceuticals Inc. [ARPO]: A deeper dive into fundamental analysis
Return on Total Capital for ARPO is now -47.35, given the latest momentum, and Return on Invested Capital for the company is -48.85. Return on Equity for this stock declined to -48.89, with Return on Assets sitting at -44.73. When it comes to the capital structure of this company, Aerpio Pharmaceuticals Inc. [ARPO] has a Total Debt to Total Equity ratio set at 0.47. Additionally, ARPO Total Debt to Total Capital is recorded at 0.46, with Total Debt to Total Assets ending up at 0.43. Long-Term Debt to Equity for the company is recorded at 0.18, with the Long-Term Debt to Total Capital now at 0.18.
Reflecting on the efficiency of the workforce at the company, Aerpio Pharmaceuticals Inc. [ARPO] managed to generate an average of -$1,939,209 per employee.Aerpio Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 13.30 and a Current Ratio set at 13.30.
Aerpio Pharmaceuticals Inc. [ARPO]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Aerpio Pharmaceuticals Inc. posted -0.21/share EPS, while the average EPS was predicted by analysts to be reported at -0.22/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 4.50%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ARPO.
An analysis of insider ownership at Aerpio Pharmaceuticals Inc. [ARPO]
There are presently around $10 million, or 24.50% of ARPO stock, in the hands of institutional investors. The top three institutional holders of ARPO stocks are: ORBIMED ADVISORS LLC with ownership of 5,193,946, which is approximately 0% of the company’s market cap and around 24.32% of the total institutional ownership; VANGUARD GROUP INC, holding 1,193,906 shares of the stock with an approximate value of $1.58 million in ARPO stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.6 million in ARPO stock with ownership of nearly 10.932% of the company’s market capitalization.
Positions in Aerpio Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 7 institutional holders increased their position in Aerpio Pharmaceuticals Inc. [NASDAQ:ARPO] by around 130,711 shares. Additionally, 7 investors decreased positions by around 1,205,010 shares, while 10 investors held positions by with 6,447,817 shares. The mentioned changes placed institutional holdings at 7,783,538 shares, according to the latest SEC report filing. ARPO stock had 4 new institutional investments in for a total of 69,741 shares, while 4 institutional investors sold positions of 1,155,948 shares during the same period.